Could a lower drug dose after stem cell transplants be safer and just as effective?

NCT ID NCT05436418

First seen Nov 01, 2025 · Last updated Jun 08, 2026 · Updated 37 times

Summary

This study is for people with blood cancers like leukemia or lymphoma who need a stem cell transplant from a donor. After transplant, a drug called cyclophosphamide is given to prevent graft-versus-host disease, a serious side effect. Researchers want to find the lowest effective dose of this drug to reduce side effects while still protecting against the disease. The trial involves 260 participants and will follow them for up to 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope

    NOT_YET_RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.